Phase 2 N=23 Study of Nicotinamide in Early Onset Preeclampsia
Pre-Eclampsia · Pregnancy Related
Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 CX-8998 for Absence Seizures
Epilepsy
Primary: Change From Baseline to End of Treatment in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) — 3.50 msec
Phase 2 N=76 A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Efficacy: Mean Changes in FVC From Baseline to Week 24 — 2608.2; 2516.7; 2608.8; 2516.7 mL
Phase 2 N=29 Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery
Cardiac Surgery Subjects · Subjects Undergoing CABG and/or Cardiac Valve Replacement
Primary: Percent Change From 0 Hour in Pulmonary Vascular Resistance (PVR) at 0.5 Hour Post-separation From Cardiopulmonary Bypass (CPB) — -7.75; -10.94; 62.22 percent change…
Phase 2 N=21 Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
PCDH19-Related Epilepsy
Primary: Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change) — -23.97; -61.52 Median % Change in Number of Seizures
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
Phase 2 N=88 Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
HER2-negative Breast Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC) — 38.2; 61.9 Percentage of participants — p=0.0210
Phase 2 N=20 Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Adenocarcinoma of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach
Primary: Disease-free Survival — 4 Participants
Phase 2 N=30 Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
Epilepsy
Primary: Summary of 28-day Seizure Frequency for Sum of Individual Seizures and Clusters for 52-week OLE Period (Mean Percent Change & Standard Deviation) — -31.23; NA; 122.10…
Phase 2 N=11 A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
Epilepsy, Complex Partial
Primary: Investigators Global Assessment — 6; 4; 0; 1 Participants
Phase 2 N=18 Cannabidiol Treatment in Patients With Early Psychosis
Schizophrenia · Schizoaffective Disorder
Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08
Phase 2 N=25 Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Serious Adverse Events as Measured by Patient Reporting — 2 Participants
Phase 2 N=152 Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Locally Advanced Papillary Renal Cell Carcinoma · Metastatic Papillary Renal Cell Carcinoma · Stage III Renal Cell Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 5.6; 9.0; 2.8; 3.0 months — p=0.019
Phase 2 N=56 Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants
Phase 2 N=305 Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — -25.66; -25.14; -29.95; -24.81 units on a scale